Earnings summaries and quarterly performance for Envista Holdings.
Executive leadership at Envista Holdings.
Paul Keel
Detailed
President and Chief Executive Officer
CEO
EH
Eric Hammes
Detailed
Senior Vice President and Chief Financial Officer
MN
Mark Nance
Detailed
Senior Vice President, General Counsel and Secretary
MR
Mischa Reis
Detailed
Senior Vice President, Strategy and Corporate Development
RB
Robert Befidi
Detailed
President, Diagnostics
SN
Stefan Nilsson
Detailed
President, Nobel Biocare
VA
Veronica Acurio
Detailed
President, Orthodontics
Board of directors at Envista Holdings.
Research analysts who have asked questions during Envista Holdings earnings calls.
Elizabeth Anderson
Evercore ISI
6 questions for NVST
Also covers: AGL, ALGN, CAH +23 more
Jeffrey Johnson
Robert W. Baird & Co. Inc.
6 questions for NVST
Also covers: ALC, ALGN, BBNX +11 more
Jonathan Block
Stifel Financial Corp.
6 questions for NVST
Also covers: ALGN, COO, CUTR +11 more
Kevin Caliendo
UBS
5 questions for NVST
Also covers: AHCO, ALGN, AMWL +15 more
Steven Valiquette
Mizuho
5 questions for NVST
Also covers: ALGN, CAH, COR +12 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
4 questions for NVST
Also covers: ALGN, CBLL, CVRX +17 more
EW
Erin Wright
Morgan Stanley
4 questions for NVST
Also covers: ALGN, BTSG, CAH +18 more
Allen Lutz
Bank of America
3 questions for NVST
Also covers: ACCD, CAH, COR +14 more
Michael Cherny
Leerink Partners
3 questions for NVST
Also covers: ACCD, ALGN, CAH +18 more
D
Dev
Bank of America
2 questions for NVST
Jason Bednar
Piper Sandler Companies
2 questions for NVST
Also covers: ALGN, COO, EDAP +15 more
Lilly Quezada
JPMorgan Chase & Co.
2 questions for NVST
Also covers: ATRC
VC
Vikramjeet Chopra
Wells Fargo & Company
2 questions for NVST
Also covers: ALGN, ATEC, CNMD +9 more
BV
Brandon Vasquez
William Blair & Company
1 question for NVST
Also covers: HSIC, ZTS
Russell Yuen
William Blair & Company
1 question for NVST
Also covers: ALGN, ENOV
VC
Vik Chopra
Wells Fargo & Company
1 question for NVST
Also covers: ALGN, ATEC, CNMD +8 more
Recent press releases and 8-K filings for NVST.
Envista Holdings Announces Q4 and FY 2025 Results and FY 2026 Guidance
NVST
Earnings
Guidance Update
Share Buyback
- Envista Holdings reported Q4 2025 Adjusted EBITDA of $111.3 million and FY 2025 Free Cash Flow of $230.9 million, with a 114% Free Cash Conversion for the full year.
- The company returned $166 million to shareholders through share repurchases in 2025, including 1.2 million shares repurchased in Q4 2025 and 9.2 million shares in FY 2025.
- For FY 2026, Envista Holdings provided guidance projecting Core Sales Growth of 2% to 4%, Adjusted EBITDA Growth of 7% to 13%, and Adjusted EPS of $1.35 to $1.45.
- Strategic and operational progress in 2025 included ~$100 million in revenue from new products and a 10% reduction in G&A spending, with actions expected to lead to a ~4 point tax rate reduction in 2026.
1 day ago
Envista Holdings Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance
NVST
Earnings
Guidance Update
Share Buyback
- Envista Holdings reported strong Q4 2025 results, with sales of $751 million and core sales growth of 10.8%. For the full year 2025, sales reached $2.7 billion with core sales growth of 6.5%. Adjusted EPS for Q4 was $0.38, and for the full year, it was $1.19.
- In 2025, Adjusted EBITDA grew 26% with a margin of 13.7%, representing a 190 basis point improvement over 2024. The company achieved strong free cash flow conversion of 114% for the full year.
- For 2026, Envista expects core revenue growth of 2%-4%, Adjusted EBITDA growth of 7%-13%, and Adjusted EPS between $1.35 and $1.45. Free cash flow conversion is projected to be around 100%.
- Key strategic actions in 2025 included reducing G&A spending by over $35 million , initiating a $250 million share repurchase program and returning over $160 million to shareholders , and generating nearly $100 million in revenues from new products.
1 day ago
Envista Holdings Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance
NVST
Earnings
Guidance Update
Share Buyback
- Envista Holdings reported a strong Q4 2025, with core growth around 11%, 22% EBITDA growth, and adjusted EPS of $0.38, representing an increase of more than 50% from Q4 2024.
- For the full year 2025, the company achieved 6.5% core growth, a 26% increase in adjusted EBITDA (resulting in a 14% margin), and EPS growth of over 60%, supported by 114% free cash flow conversion.
- Strategic actions in 2025 included a reduction in G&A spending by over $35 million and the return of over $160 million to shareholders through a share repurchase program.
- Envista provided 2026 guidance, projecting core revenue growth of 2%-4%, adjusted EBITDA dollar growth of 7%-13%, adjusted EPS between $1.35-$1.45, and free cash flow conversion around 100%.
- The company anticipates Volume-Based Procurement (VBP) for ortho and a second round for implants in China during 2026, with the ortho VBP expected to be a net benefit to revenues, similar to the first implant VBP.
1 day ago
Envista Holdings Reports Strong Q4 and Full-Year 2025 Results, Provides Positive 2026 Guidance
NVST
Earnings
Guidance Update
Share Buyback
- Envista Holdings reported strong financial results for Q4 and full-year 2025, with Q4 sales of $751 million and 10.8% core sales growth, and full-year sales of $2.7 billion with 6.5% core sales growth. Adjusted EPS for Q4 was $0.38 (up over 50% year-over-year) and for the full year was $1.19 (up over 60% year-over-year).
- The company exceeded its medium-term financial objectives in 2025, achieving 26% Adjusted EBITDA growth (resulting in a 13.7% margin) and 114% free cash flow conversion.
- For 2026, Envista Holdings provided positive guidance, expecting core revenue growth of 2%-4%, Adjusted EBITDA dollar growth of 7%-13%, and Adjusted EPS between $1.35 and $1.45. Free cash flow conversion is projected to be around 100%.
- Strategic actions in 2025 included reducing G&A spending by over $35 million and returning over $160 million to shareholders through a share repurchase program. New products contributed close to $100 million in revenues.
- The dental market is characterized as slow but stable, with potential for modest improvement. The company's 2026 guidance incorporates assumptions for a second implant VBP in Q2 and an ortho 1.0 VBP in H2 in China.
1 day ago
Envista Holdings Reports Fourth Quarter and Full-Year 2025 Results
NVST
Earnings
Guidance Update
Share Buyback
- Envista Holdings Corporation reported Q4 2025 sales of $751 million with 10.8% core revenue growth, and FY 2025 sales of $2,719 million with 6.5% core revenue growth.
- For Q4 2025, adjusted diluted EPS was $0.38 (+58% year-on-year) and adjusted EBITDA was $111 million (+22% year-on-year). For FY 2025, adjusted diluted EPS was $1.19 (+63% year-on-year) and adjusted EBITDA was $372 million (+26% year-on-year).
- The company returned $166 million to shareholders through share repurchases in FY 2025, repurchasing 9.2 million shares.
- Envista provided full-year 2026 guidance, expecting core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, and adjusted diluted EPS of $1.35 to $1.45.
1 day ago
Envista Highlights Strong Q3 2025 Performance and Market Leadership at J.P. Morgan Conference
NVST
Guidance Update
Revenue Acceleration/Inflection
Earnings
- Envista (NVST) presented at the J.P. Morgan Healthcare Conference 2026, highlighting its leadership in the dental market, which is expected to return to a 3-5% long-term growth rate.
- The company's Value Creation Plan, initiated last March, has led to encouraging financial performance, including year-to-date Q3 2025 organic growth of 5% and strong double-digit increases in adjusted EBITDA and EPS.
- For the third quarter of 2025, Envista reported 9.4% Core sales growth, Adjusted EBITDA of $97.1 million, and Free Cash Flow of $67.9 million with a 126% FCF to Adjusted Net Income Conversion Ratio.
Jan 12, 2026, 11:45 PM
Envista Highlights Strong Q3 2025 Performance and Strategic Progress
NVST
Revenue Acceleration/Inflection
Share Buyback
New Projects/Investments
- Envista reported 5% organic growth year-to-date through Q3 2025, surpassing its medium-term target of 2-4%. This was accompanied by strong double-digit growth in EBITDA and EPS and 100% cash flow conversion for the same period.
- The Spark Clear Aligner business, now approximately $300 million, has turned profitable and is expected to continue expanding margins towards the company's fleet average of around 14% for 2025, primarily driven by factory automation.
- The implants business, after contracting in 2023 and the first half of 2024, has achieved four consecutive quarters of positive growth through Q3 2025, supported by a $25 million investment in 2024.
- Envista anticipates the dental market will return to its long-term 3%-5% growth rate, citing positive indicators such as mid-single digit U.S. clinic revenue growth in Q3 2025, low unemployment, and lowering interest rates.
- The company reduced G&A spending by 12% in the first three quarters of 2025 and deployed just over half of its $250 million share purchase program authorized at the beginning of 2025. A meaningful reduction in the effective tax rate is expected for 2026, with a target of the mid-20s%.
Jan 12, 2026, 11:45 PM
Envista Provides Update on Value Creation Plan and Market Outlook
NVST
Revenue Acceleration/Inflection
Share Buyback
New Projects/Investments
- Envista reported strong financial performance through Q3 2025, with 5% organic growth and double-digit growth in EBITDA and EPS, aligning with its medium-term objectives of 2%-4% organic revenue growth, 4%-7% EBITDA growth, and 7%-10% EPS growth.
- The dental market is showing signs of returning to its historical 3%-5% growth rate in 2026, supported by favorable macro indicators, while Envista's Spark clear aligner business has become profitable and its implants business achieved four consecutive quarters of positive growth.
- The company reduced G&A spending by 12% through Q3 2025 and expects a meaningful reduction in its effective tax rate for 2026, aiming for the mid-20s%, following the resolution of an intercompany loan.
- Envista authorized a $250 million share purchase program, deploying over half of it in the first three quarters of 2025, and increased R&D and sales & marketing investments to accelerate growth.
Jan 12, 2026, 11:45 PM
Envista Highlights Strong Q1-Q3 2025 Performance and Positive Dental Market Outlook
NVST
Revenue Acceleration/Inflection
Share Buyback
Product Launch
- Envista reported strong financial performance for the first three quarters of 2025, achieving 5% organic growth, double-digit growth in EBITDA and EPS, and approximately 100% free cash flow conversion.
- The company's Spark Clear Aligner business has become profitable and is now a $300 million business, with underlying primary case start growth in the mid-to-high single digits. Its profitability expansion is primarily driven by factory automation.
- Envista is observing positive momentum in the dental market, with signs of returning to its long-term 3%-5% growth rate, supported by stabilized patient demand, new clinic openings, low unemployment, and lowering interest rates. The diagnostics category also returned to growth in the second half of 2025.
- The implants business achieved four consecutive quarters of positive growth after a period of contraction, following a $25 million investment in 2024 focused on commercial execution, customer education, and new products.
- Envista reduced G&A spending by 12% in the first three quarters of 2025 and expects a meaningful reduction in its tax rate in 2026, aiming for the mid-20s%. The company also deployed over half of its $250 million share purchase program in the first three quarters of 2025.
Jan 12, 2026, 11:45 PM
Envista Provides Market Outlook and Updates on Performance, Margins, and Capital Deployment
NVST
Guidance Update
Share Buyback
New Projects/Investments
- Envista characterizes the overall dental market as soft but stable, with low single-digit growth, and anticipates a strong finish to the year.
- The company has achieved approximately 5% year-to-date growth, with its Spark aligner business growing above market share driven by product innovation and a comprehensive solution strategy.
- Margin expansion efforts include a 20% year-over-year cost reduction per aligner for Spark and a 12% year-to-date reduction in G&A (in dollars).
- Envista updated its tax rate guidance from 37% to 33% mid-year, expecting a significant tailwind in 2026 due to the resolution of an intercompany loan, bringing the rate "much below 33%".
- Capital deployment priorities focus on organic growth and accretive M&A, alongside a $250 million share purchase program over two years approved earlier this year.
Dec 3, 2025, 5:30 PM
Quarterly earnings call transcripts for Envista Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more